PETERSON RICHARD D

Form 4

December 13, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB

3235-0287 Number:

OMB APPROVAL

January 31, Expires: 2005

Estimated average burden hours per response... 0.5

if no longer subject to Section 16. Form 4 or

Check this box

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

Common

Common

Common

Stock

Stock

12/06/2012

12/11/2012

12/11/2012

(Print or Type Responses)

1. Name and Address of Reporting Person * PETERSON RICHARD D	2. Issuer Name and Ticker or Trading Symbol MEDICIS PHARMACEUTICAL CORP [MRX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 7720 N. DOBSON RD.	3. Date of Earliest Transaction (Month/Day/Year) 12/06/2012	Director 10% Owner Officer (give title Other (specify below) EVP, CFO & Corp Treasurer			
(Street)	4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check			
SCOTTSDALE, AZ 85256	Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State) (Zip)	Table I - Non-Derivative Securities Acc	quired, Disposed of, or Beneficially Owned			
(Instr. 3) any	med 3. 4. Securities Acquired on Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Day/Year) (Instr. 8)	5. Amount of Securities Ownership Indirect Beneficially Form: Direct Beneficial Owned (D) or Ownership			

Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Code

G

D

D

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control

Following

Reported

205,889

Transaction(s)

(Instr. 3 and 4)

(A)

or

(D)

D

D

D

Price

\$0

\$44 0

\$ 44 0

Amount

205,889

(1)(2)

 $102 \frac{(3)}{2}$

V 2,300

Indirect (I)

(Instr. 4)

D

D

Ι

(Instr. 4)

By 401(k)

Plan

Edgar Filing: PETERSON RICHARD D - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	e Expiration Date (Month/Day/Year) (A) ed of		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option	\$ 38.45	12/11/2012		D	36,000	<u>(4)</u>	07/16/2014	Common Stock	36,000

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

PETERSON RICHARD D 7720 N. DOBSON RD. SCOTTSDALE, AZ 85256

EVP, CFO & Corp Treasurer

Signatures

Richard D. 12/13/2012 Peterson

**Signature of Date
Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Amount of Securities Beneficially Owned in Column 5 reflects a transfer to the reporting officer's former spouse of 9,000 shares on August 23, 2012, pursuant to a divorce settlement decree.
 - On December 11, 2012, the Issuer completed its merger (the "Merger") with Valeant Pharmaceuticals International ("Valeant"), whereby the Issuer became a wholly owned subsidiary of Valeant, pursuant to an Agreement and Plan of Merger that was entered into on
- September 2, 2012 (the "Merger Agreement"). In accordance with the Merger Agreement, each share of common stock of the Issuer issued and outstanding immediately prior to the consummation of the Merger converted into a right to receive an amount in cash equal to \$44.00 per share (the "Per Share Merger Consideration"), without interest. The amount of shares in Column 4 includes 188,890 restricted shares of common stock that also converted into a right to receive the Per Share Merger Consideration.
- (3) Common stock of the Issuer held within the reporting person's 401(k) plan immediately prior to the consummation of the Merger converted into a right to receive the Per Share Merger Consideration.
- (4) In accordance with the terms of the Merger Agreement, each option to acquire shares of the Issuer (whether vested or unvested) that was outstanding immediately prior to the consummation of the Merger was cancelled in exchange for the right to receive an amount in cash

Reporting Owners 2

Edgar Filing: PETERSON RICHARD D - Form 4

equal to the product of the number of shares of Issuer common stock subject to the option and the excess, if any, of the Per Share Merger Consideration over the exercise price per share of each respective award, less any required withholding taxes. This award had fully vested prior to the consummation of the Merger.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.